Skip to contentHome page Seeking Alpha - Power to InvestorsNov 21, 2026, 4:01 AM ETZimmer Biomet Holdings, Inc. (ZBH) StockMayank Marwah36 FollowersSummaryZimmer Biomet had a strong third quarter, driven by robust sales and strong cash flow.Strong growth in the Hips, technology, and robotics segments offset the weak knee sales in Q3.My DCF valuation says the stock should be priced at around $124 per share. Given the current price of $101.47, the stock is undervalued by roughly 23%.Since knee business is shrinking, I would suggest a buy. However, build your position slowly as the business improves.jetcityimage/iStock Editorial via Getty ImagesMy Investment ThesisZimmer Biomet (ZBH) came out with its third quarter financial results on November 4, 2026. Q3 was a strong quarter for the company, as net sales jumped 3.1% asThis article was written byMayank Marwah36 FollowersI am a Chartered Accountant based in India (Equivalent of a US CPA). I like covering stocks that most people don't talk about, and closely look at the numbers to find good investment ideas that the market may have missed. I am closely associated with NM Market Insights.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.ShareCommentsQuick InsightsStrong cash generation, improving sales and raised guidance underpin the buy case. A DCF using a 7.9% discount rate and 2.5% terminal growth rate yields $124.48 per share, roughly 23% above the $101.47 stock price.The buy case assumes knee sales stabilize after a 3.1% Q3 decline tied to China distributor consolidation and sales-force disruption. Hips and robotics growth help offset weakness, but further knee deterioration would weaken the thesis.Net debt was $7.10 billion, roughly 6.1 times 2025 free cash flow, with $1.29 billion due within a year. Shareholder returns consumed approximately 78% of nine-month free cash flow, limiting deleveraging and leaving less room for error if cash flow weakens.Recommended For You